An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora

Chemotherapy

Volumn 49, Issue 1-2, 2003, Pages 17-23

  Vermes, András ^a,b   Kuijper, Ed J ^a   Guchelaar, Henk Jan ^a   Dankert, Jacob ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Conversion; Flucytosine; Fluorouracil; Microorganisms; Toxicity

Indexed keywords

AMPHOTERICIN B; CIPROFLOXACIN; COTRIMOXAZOLE; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; NYSTATIN; PENICILLIN G;

ADULT; ARTICLE; BACTERIAL GROWTH; BACTERIUM COLONY; CASE REPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FECES LEVEL; DRUG METABOLISM; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; HUMAN; INCUBATION TIME; INTESTINE FLORA; MALE; NEUTROPENIA; PRIORITY JOURNAL; SCHOOL CHILD;

ANTIFUNGAL AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; FECES; FEMALE; FLUCYTOSINE; FLUOROURACIL; HUMANS; INTESTINES; MALE; MIDDLE AGED; NEUTROPENIA;

EID: 0344942468     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069784     Document Type: Article

References (31)

1. Duschinsky R, Pleven E, Heidelberger C: The synthesis of 5-fluoropyrimidines. J Am Chem Soc 1957;79:4559-4560.
2. Heidelberger C, Griesbach L, Montag BJ, Mooren D, Cruz O, Schnitzer RJ, Grunberg E: Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Res 1958;18:305-317.
3. Grunberg E, Titsworth E, Bennett M: Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother 1964;3:566-568.
4. Tassel D, Madoff MA: Treatment of Candida species and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA 1968;206:830-832.
5. Utz JP, Tynes BS, Shadomy HJ, Duma RJ, Kannan MM, Mason KN: 5-Fluorocytosine in human cryptococcosis. Antimicrob Agents Chemother 1969;8:344-346.
6. Benson JM, Nahata MC: Clinical use of systemic antifungal agents. Clin Pharm 1988;7:424-438.
7. Graybill JR, Craven PC: Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs 1983;25:41-62.
8. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradhaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-131.
9. Francis P, Walsh TJ: Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and anti-fungal therapy. Clin Infect Dis 1992;15:1003-1018.
10. Bennett JE: Flucytosine. Ann Intern Med 1977; 86:319-321.
11. Diasio RB, Bennett JE, Myers CE: Mode of action of 5-fluorocytosine. Biochem Pharmacol 1978;27:703-707.
12. Polak A, Scholer HJ: Mode of action of 5-fluorocytosine. Rev Inst Pasteur Lyon 1980;13:233-244.
13. Bennett JE: Antimicrobial agents. Antifungal agents; in Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 1996, pp 1175-1190.
14. Scholer HJ: Flucytosine; in Speller DCE (ed): Antifungal Chemotherapy. New York, Wiley, 1980, pp 35-106.
15. Waldorf AR, Polak A: Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother 1983;23:79-85.
16. Eilard T, Alestig K, Wahlén P: Treatment of disseminated candidiasis with 5-fluorocytosine. J Infect Dis 1974;130:155-159.
17. Kauffman CA, Frame PT: Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 1977;11:244-247.
18. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, Karam GH, Espinel-Ingroff A: Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987;83:236-242.
19. Utz JP, Garriques IL, Sande MA, Warner JF, Mandell LG, McGehee RF, Duma RJ, Shadomy S: Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis 1975;132:368-373.
20. Vermes A, van der Sijs IH, Guchelaar HJ: Flucytosine: Correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000;46:86-94.
21. Diasio RB, Lakings DE, Bennett JE: Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: Possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother 1978;14:903-908.
22. Harris BE, Manning BW, Federle TW, Diasio RB: Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother 1986;29:44-48.
23. Malet-Martino MC, Martino R, de Forni M, Andremont A, Hartmann O, Armand JP: Flucytosine conversion to fluorouracil in humans: Does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy. Infection 1991;19:178-180.
24. Vialaneix JP, Malet-Martino MC, Hoffmann JC, Pris J, Martino R: Direct detection of new flucytosine metabolites in human biofluids by 19F nuclear magnetic resonance. Drug Metab Dispos 1987;15:718-724.
25. Williams KM, Duffield AM, Christopher RK, Finlayson OJ: Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry. Biomed Mass Spectrom 1981;8:179-182.
26. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-Analysis Group in Cancer. J Clin Oncol 1998;16:301-308.
27. Toxicity of fluorouracil compared in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol 1998;16:3537-3541.
28. Vermes A, van der Sijs IH, Guchelaar HJ: An accelerated stability study of 5-flucytosine in intravenous solution. Pharm World Sci 1999;21:35-39.
29. Sastre Toraño J, Vermes A, Guchelaar HJ: Simultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography. Biomed Chromatogr 2001;15:89-94.
30. Gamelin B, Biosdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F, Robert J: Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998;16:1470-1478.
31. Ignoffo RJ: Noval oral fluoropyrimidines in the treatment of metastatic colorectal cancer. Am J Health Syst Pharm 1999;56:2417-2430.